Scryb Highlights New U.S. Institutional Fund Investment in Cybeats; Strengthens Long-Term Outlook
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to highlight the closing of an investment by U.S.-based IFCM MicroCap Fund LP, managed by Intelligent Fanatics Capital Management, into Cybeats Technologies Corp. ("Cybeats"). The investment fund was the sole participant in this $1.44 million private placement.1 Scryb maintains its position as the largest institutional shareholder of Cybeats
Biotechnology, Healthcare and Hospitals, Health
2025-11-17 7:00 AM EST | Scryb Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2026 ended September 30, 2025 ("Second Quarter"). Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, an increase of $17.4 million or approximately 92% as compared to the comparable period
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-14 4:19 PM EST | Elite Pharmaceuticals, Inc.
RETRANSMISSION: Akanda Researching Security Requirements for Full Cultivation License
Toronto, Ontario--(Newsfile Corp. - November 14, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potenti
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-11-14 8:30 AM EST | Akanda Corp
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment
Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This milestone marks another key step in Cosmo’s mission to build health confidence worldwide, expanding access to
Healthcare and Hospitals, Health
2025-11-14 1:10 AM EST | Cosmo Pharmaceuticals N.V.
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Safety Monitoring Committee Issues Favorable Review of Safety Data at Maximum Dose of INTASYL PH-762 Warrant Inducement Fi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-13 4:15 PM EST | Phio Pharmaceuticals Corp.
Akanda Researching Security Requirements for Full Cultivation License
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potenti
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-11-13 4:05 PM EST | Akanda Corp
BioHarvest Sciences Reports Third Quarter 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a
Biotechnology, Pharmaceuticals, Health
2025-11-13 4:05 PM EST | BioHarvest Sciences Inc.
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation (to the University of Florida (UF, Gainesville) vascular team. The session, titled "Angiogenic Cell Precursors (ACP-01): Regenerating Microcirculation in CLI, Cardiomyopathy and Angina," was delivered by Fraser Henderson Sr., MD (neurosurgeon) with opening remarks and poli
Biotechnology, Pharmaceuticals, Health
2025-11-13 10:57 AM EST | Hemostemix Inc.
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market. This allowance fortifies Cardiol's global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-13 7:45 AM EST | Cardiol Therapeutics Inc.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise. Key business update Medexus is currently focused on delivering strong p
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 6:06 PM EST | Medexus Pharmaceuticals Inc.
Restart Life Sciences Announces Private Placement Financing
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units in the capital of the Company (each, a "Unit") at a price of CAD $0.10 per Unit for aggregate gross proceeds of up to CAD $1,000,000 (the "Offering"). Each Unit purchased will include one common share and one transferable common share p
Technology, Biotechnology, Health
2025-11-12 4:22 PM EST | Restart Life Sciences Corp.
Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol
Winter Park, Florida--(Newsfile Corp. - November 12, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes. This Patent Pending innovation represents a significant advancement in ADIA's mission to deliver cutting-edge, science-backed therapies. The proprie
Healthcare and Hospitals, Health
2025-11-12 9:15 AM EST | Adia Nutrition Inc.
BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Craig-Hallum 16th Annual Alpha Select Conference taking place on Tuesday, November 18th, 2025 in New York, NY.
Biotechnology, Pharmaceuticals, Health
2025-11-12 8:42 AM EST | BioHarvest Sciences Inc.
Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation
Sacramento, California--(Newsfile Corp. - November 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of the second episode in its podcast series:
2025-11-12 8:00 AM EST | Izotropic Corporation
Rock Salt Marketing Appoints Spencer Bierman as New SEO Director
Salt Lake City, Utah--(Newsfile Corp. - November 12, 2025) - Award-winning Utah- and Tennessee-based digital marketing agency Rock Salt Marketing has announced the appointment of Spencer Bierman as its new SEO Director.
Real Estate, Travel, Health, Legal
2025-11-12 7:30 AM EST | Rock Salt Marketing Cooperative
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
Northvale, New Jersey--(Newsfile Corp. - November 12, 2025) - Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropi
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 7:00 AM EST | Elite Pharmaceuticals, Inc.
Red Light Holland's Wholly Owned Subsidiary Happy Caps Expands Safeway Partnership to 123 Stores Across the U.S. Pacific Northwest, in Time for American Thanksgiving
Toronto, Ontario--(Newsfile Corp. - November 11, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, is pleased to announce a major U.S. retail expansion milestone for its wholly owned subsidiary, 4316747 Nova Scotia Limited o/a Happy Caps Mushroom Farm ("Happy Caps") with Albertso
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-11-11 8:39 AM EST | Red Light Holland Corp.
Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal
Dublin, Ireland--(Newsfile Corp. - November 11, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership. Cosmo’s 2025 S&P Global Corporate Sustainability Assessment has been upgraded to the 67th percentile, a significant improvement from la
Healthcare and Hospitals, Health
2025-11-11 1:01 AM EST | Cosmo Pharmaceuticals N.V.
CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000. The
Technology, Healthcare and Hospitals, Health
2025-11-10 11:37 PM EST | CardioComm Solutions, Inc.
LevelJump Announces 2025 Third Quarter Results
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and nine months ended September 30, 2025. Financial and Operational Highlights Revenues were $4.84 million in the third quarter compared to $4.45 million in the same period the prior year, an increase of 8.7%. For the nine months ended S
Healthcare and Hospitals, Health
2025-11-10 10:31 PM EST | LevelJump Healthcare Corp.